List of Excipients in Branded Drug CHILDRENS ALLEGRA ALLERGY

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chattem Inc	CHILDRENS ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4232	ASPARTAME
Chattem Inc	CHILDRENS ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4232	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	CHILDRENS ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4232	CROSPOVIDONE

Children’s Allegra Allergy Excipient Strategy and Commercial Opportunities

Last updated: September 7, 2026

Children’s Allegra Allergy is a U.S. over-the-counter fexofenadine hydrochloride product sold in multiple pediatric dosage forms, including oral suspension and solid-dose products. The main excipient opportunity is not active-ingredient differentiation. Fexofenadine is a mature, widely available antihistamine. Commercial value is concentrated in taste masking, dosing accuracy, preservative systems, sugar reduction, tablet disintegration, packaging, and age-specific delivery formats.

The analysis below focuses on the U.S. Children’s Allegra Allergy portfolio and the fexofenadine hydrochloride 30 mg/5 mL oral suspension. Exact excipients and regulatory status vary by stock-keeping unit and market.

What is Children’s Allegra Allergy?

Children’s Allegra Allergy contains fexofenadine hydrochloride, a second-generation H1 antihistamine used for relief of seasonal allergic rhinitis and related symptoms. The pediatric liquid product is labeled at 30 mg per 5 mL and is intended for children within the age range specified on the package labeling. Solid-dose pediatric products generally use 30 mg units.

Product attribute	Commercial assessment
Active ingredient	Fexofenadine hydrochloride
Therapeutic class	Second-generation antihistamine
U.S. status	OTC product
Principal pediatric liquid strength	30 mg/5 mL
Primary dosage forms	Oral suspension or liquid; chewable or orally disintegrating products may be marketed depending on SKU
Primary use	Seasonal allergic rhinitis and allergy symptoms
Primary excipient issues	Taste, viscosity, dose uniformity, sedimentation, preservative compatibility, sugar content and palatability
Primary commercial competitors	Children’s Zyrtec, Children’s Claritin, store-brand cetirizine, loratadine and fexofenadine products

Fexofenadine has low central nervous system penetration relative to older antihistamines. The product’s commercial positioning therefore depends heavily on non-sedating use, pediatric convenience and consumer trust rather than novel pharmacology.

What excipients are used in Children’s Allegra Allergy liquid?

The liquid formulation uses a conventional pediatric suspension architecture. Public product labeling identifies inactive ingredients that may include viscosity modifiers, sweetening agents, buffering agents, preservatives, chelating agents, colorants, flavors and purified water. The precise list must be evaluated against the current package insert for the specific marketed SKU because formulations can change across manufacturing sites and countries.

Functional excipient roles

Excipient function	Formulation objective	Commercial relevance
Suspending or thickening agent	Keeps fexofenadine particles dispersed and supports dose uniformity	Reduces underdosing from rapid settling
Sweetener	Masks bitterness and improves acceptance	Directly affects repeat purchase and adherence
Flavor system	Covers active and preservative notes	Supports pediatric acceptability
Buffer	Controls pH and supports chemical stability	Influences taste, preservative activity and packaging compatibility
Preservative	Controls microbial growth in a multidose aqueous product	Important for shelf life and in-use safety
Chelator	Reduces metal-catalyzed degradation and may improve preservative performance	Can support stability without increasing preservative concentration
Colorant	Provides product recognition	May create allergen, consumer-perception and regional compliance issues
Humectant or polyol	Adjusts mouthfeel and sweetness	Can improve texture but may affect gastrointestinal tolerance
Purified water	Continuous liquid phase	Determines microbial and container-closure control requirements

The highest-value formulation problem is taste. Fexofenadine is not an ideal pediatric liquid active because bitterness, acidity, preservative flavor and polymer mouthfeel can combine into a persistent aftertaste. A successful formulation must balance palatability with suspension stability and dose reproducibility.

What excipient strategy best supports a pediatric fexofenadine suspension?

A commercially optimized strategy should use a low-sugar or sugar-free, alcohol-free suspension with robust dose uniformity and a flavor system tested in children or pediatric sensory panels.

Taste masking

Taste masking can combine sweeteners, flavor layering and polymer-based approaches. A single high-intensity sweetener is unlikely to solve the problem because bitterness can persist after the initial sweetness. A more defensible platform uses:

1. Immediate sweetness from a bulk sweetener or polyol.
2. Delayed or lingering sweetness from a high-intensity sweetener.
3. Fruit-based flavor notes that cover bitterness and preservative taste.
4. A controlled pH that reduces sharp acidity without compromising stability.

The formulation should avoid excessive sweetness that creates dental-health concerns or an artificial aftertaste. Flavor selection also needs to account for age segmentation. Younger children often accept berry profiles, while older children may prefer a less medicinal citrus or fruit profile.

Suspension stability

A pediatric suspension must deliver an accurate dose after storage, transport and routine household use. Critical performance tests include:

• Sedimentation rate.
• Redispersibility after standing.
• Dose uniformity at the beginning, middle and end of the bottle.
• Viscosity across temperature ranges.
• Pourability through the supplied dosing device.
• Compatibility with oral syringes and dosing cups.

A formulation that is too thin can settle rapidly and produce dose variability. A formulation that is too thick can resist pouring, trap air in an oral syringe or create inaccurate dosing. The optimal system is usually a controlled-flocculation or structured-vehicle approach rather than maximum viscosity.

Preservative and packaging design

Multidose aqueous products require a microbial-control strategy. A preservative system must remain effective across the product’s pH range and must be compatible with the bottle, cap, liner and dosing device.

Commercially attractive options include:

• A lower-preservative system supported by a validated bottle and closure.
• A preservative-free single-dose or unit-dose presentation.
• A multidose bottle with a dosing syringe and tamper-evident closure.
• A package using an air-reduction or metered-dispensing design.

Preservative reduction can support a “sensitive child” positioning, although such claims require substantiation and regulatory review. Preservative-free packaging generally increases cost and may reduce the price competitiveness of an OTC product.

What formulations are protected by patents?

Children’s Allegra Allergy is unlikely to derive meaningful commercial exclusivity from the fexofenadine molecule itself. Fexofenadine hydrochloride is a mature active ingredient with generic availability. The defensible IP layer, if any, is more likely to involve a specific formulation, delivery system, dosing device, manufacturing process or brand asset than the active ingredient.

Potential formulation claims could cover:

• A defined pH and viscosity range.
• A specific polymer suspension system.
• A taste-masked fexofenadine composition.
• A preservative combination.
• A low-sugar or sugar-free liquid.
• A particular particle-size distribution.
• A unit-dose or metered-dose package.
• A dosing device calibrated for the 30 mg/5 mL strength.

These claims face substantial validity and freedom-to-operate pressure because pediatric suspensions, taste masking, polymers, preservatives and oral dosing devices are crowded technology areas. A patent strategy would need narrow, reproducible claim limitations supported by comparative data.

Patent-strength assessment

IP category	Expected strength	Commercial implication
Fexofenadine compound patents	Low for new-product exclusivity	Generic competition remains available
Basic liquid suspension claims	Low to moderate	Vulnerable to obviousness and prior-art challenges
Specific taste-masking composition	Moderate if supported by unexpected sensory data	May protect a differentiated pediatric product
Dosing-device integration	Moderate	Can create a package-level barrier
Manufacturing process	Moderate to high if difficult to reproduce	May protect quality and dose uniformity
Trademark and trade dress	Potentially strong	Important for OTC shelf recognition
Regulatory exclusivity	Limited for a mature OTC active	Does not replace patent protection

When does Children’s Allegra Allergy lose exclusivity?

Children’s Allegra Allergy does not depend on a conventional prescription-drug exclusivity period in the same way as a newly approved NDA product. The product competes in the U.S. OTC market, where fexofenadine products can be marketed under applicable FDA requirements and monograph conditions or through an approved application.

The practical loss-of-exclusivity event occurred when fexofenadine became broadly available in generic and store-brand forms. Brand protection now depends on consumer recognition, retail distribution, formulation convenience and execution.

Exclusivity mechanism	Relevance to Children’s Allegra Allergy
New chemical entity exclusivity	Not commercially relevant to mature fexofenadine products
Five-year NCE protection	Not applicable to the current OTC brand position
Paragraph IV exclusivity	Generally associated with ANDA patent challenges, not the principal OTC brand mechanism
Pediatric exclusivity	Could apply only in a specific qualifying regulatory context; it is not the core current barrier
Orange Book-listed patents	Must be checked by product and application; OTC brand protection is not presumed from brand status
Trademark protection	Important continuing barrier
Formulation patents	Potentially relevant if a specific product has valid, enforceable claims
Retail and advertising investment	Commercially important but not statutory exclusivity

What is the Orange Book status of Children’s Allegra Allergy?

The Orange Book is primarily a reference for approved prescription and certain listed drug applications, including patents and exclusivity associated with approved applications. A branded OTC product should not be assumed to have a meaningful Orange Book patent estate merely because it is marketed under a major brand.

For Children’s Allegra Allergy, the relevant diligence questions are:

1. Whether the specific product is associated with an FDA-approved application.
2. Whether the specific dosage form and strength have listed patents.
3. Whether any listed patent covers the marketed pediatric formulation rather than an unrelated fexofenadine product.
4. Whether generic applicants can rely on an OTC monograph pathway or must submit an application.

A product-level Orange Book review should be performed against the exact application number and dosage form. Without that linkage, an Orange Book conclusion would not be reliable. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations remains the controlling public reference for listed patents and exclusivity entries where applicable [1].

Are there Paragraph IV challenges to Children’s Allegra Allergy?

Paragraph IV litigation is a central generic-entry mechanism for approved prescription products with listed patents. It is less likely to be the main competitive pathway for a mature OTC fexofenadine product marketed under monograph conditions.

Generic and store-brand competitors can challenge the commercial position through:

• OTC monograph compliance.
• An abbreviated application where applicable.
• Private-label licensing.
• Retailer-specific branding.
• Formulation substitution.
• Lower pricing and promotional placement.

A Paragraph IV strategy would matter only if the relevant Children’s Allegra product has an approved application with enforceable listed patents. The key risk is therefore not a presumed Paragraph IV event but the absence of a durable product-specific barrier.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue several opportunities around pediatric fexofenadine products.

Premium suspension platforms

A supplier can offer a ready-to-use pediatric suspension platform with:

• Improved redispersibility.
• Lower viscosity at the point of dosing.
• Better physical stability during shipping.
• Compatibility with common preservatives.
• Reduced sugar content.
• Neutral or fruit flavor compatibility.

The strongest value proposition is a measurable reduction in dose variability and a demonstrated improvement in sensory acceptance.

Taste-masking systems

Taste-masking technologies have the highest differentiation potential. Opportunities include ion-exchange resins, polymer coatings, lipid barriers, complexation systems and multiparticulate approaches. For an OTC pediatric product, the technology must remain inexpensive enough for mass retail and must not create a gritty mouthfeel or prolonged aftertaste.

Preservative-reduction systems

A validated preservative-reduction platform could support a sensitive-consumer product line. This opportunity is strongest when paired with a controlled-dose bottle or unit-dose packaging. Microbiological validation, extractables and leachables, and in-use stability are critical development requirements.

Dosing and packaging systems

Packaging suppliers can create value through:

• Oral syringes marked for age-appropriate doses.
• Bottle adapters that reduce spills.
• Metered-dose pumps.
• Unit-dose sachets or cups.
• Child-resistant closures with improved usability.
• Packaging that minimizes sediment disturbance and dosing error.

The dosing device is a practical differentiation point because parents often value accurate administration more than small differences in flavor.

How does Children’s Allegra compare with Children’s Zyrtec and Claritin?

Attribute	Children’s Allegra	Children’s Zyrtec	Children’s Claritin
Active ingredient	Fexofenadine	Cetirizine	Loratadine
Product positioning	Non-drowsy allergy relief	Long-duration allergy relief	Non-drowsy allergy relief
Pediatric liquid opportunity	Taste, suspension and dosing	Taste and liquid acceptability	Taste and liquid acceptability
Generic competition	High	High	High
Key commercial lever	Palatability and perceived non-sedation	Efficacy perception and duration	Brand familiarity and non-sedation
Excipient differentiation	Strong opportunity in liquid and ODT formats	Similar opportunity	Similar opportunity

Children’s Allegra competes in a crowded class where active-ingredient differences are difficult to sustain as a commercial advantage. Excipient performance can influence repeat purchase, but only if consumers notice easier dosing, better taste, lower mess or fewer complaints about sedation.

What manufacturing and IP barriers exist?

The main manufacturing barriers are process control rather than raw-material scarcity. A manufacturer must control particle size, wetting, suspension formation, homogenization, filling accuracy, microbial limits and container-closure performance.

Important technical risks include:

• Fexofenadine settling during filling.
• Inconsistent bulk suspension viscosity.
• Adsorption to packaging or dosing devices.
• Preservative loss into plastic components.
• Flavor instability.
• Color variation.
• Sediment compaction after temperature cycling.
• Inaccurate dosing after incomplete shaking.

A supplier with validated scale-up data, robust raw-material specifications and a proven pediatric suspension platform can gain a meaningful commercial advantage even without a broad composition patent.

What generic launch risks exist?

Generic or store-brand entrants face low active-ingredient barriers but still encounter practical formulation challenges. The most likely launch strategies are:

1. Low-cost conventional suspension.
2. Store-brand equivalent using the same general strength and dosing profile.
3. Chewable or orally disintegrating tablet.
4. Sugar-free or dye-free reformulation.
5. Retailer-exclusive packaging.
6. Private-label product supplied by a contract manufacturer.

The incumbent risk is highest in retail channels where consumers compare price and package size. The brand can defend share through strong flavor acceptance, reliable dosing, broad distribution and differentiated packaging, but these advantages are commercial rather than statutory.

What licensing deals could support the product?

Potential licensing targets include:

• Taste-masking technology providers.
• Pediatric suspension platforms.
• Low-sugar excipient systems.
• Oral thin-film or orally disintegrating delivery technologies.
• Metered-dose packaging companies.
• Flavor houses with pediatric sensory data.
• Contract manufacturers with OTC liquid capabilities.

The most attractive deal structure would likely combine an excipient or delivery license with manufacturing rights and performance milestones. A broad platform license without product-specific sensory or stability data would have limited value.

Key Takeaways

• Children’s Allegra Allergy is a mature fexofenadine OTC brand with limited molecule-level exclusivity.
• The principal excipient opportunity is the pediatric liquid formulation.
• Taste masking, suspension stability, preservative optimization and dosing accuracy are the highest-value technical priorities.
• Formulation patents may provide protection, but broad claims in this area face crowded prior art.
• Orange Book and Paragraph IV relevance depends on the exact product application and listed patents.
• Generic and store-brand competition is structurally strong.
• Excipient suppliers can differentiate through sensory data, dose uniformity, low-sugar systems and packaging integration.
• Commercial success depends more on formulation execution, retail access and brand equity than on active-ingredient IP.

FAQs About Children’s Allegra Allergy Excipient Strategy

What is the main formulation weakness of pediatric fexofenadine liquid?

Taste and aftertaste are the main formulation challenges, followed by sedimentation, preservative flavor and dosing variability.

Is Children’s Allegra Allergy sugar-free?

The answer depends on the specific product and current label. The exact inactive-ingredient statement should be checked for the marketed SKU because liquid and solid products can use different sweeteners and excipient systems.

Can a generic manufacturer copy Children’s Allegra Allergy?

A manufacturer can generally compete with fexofenadine through an applicable OTC or abbreviated regulatory pathway, subject to FDA requirements. Copying a protected formulation, trademark, trade dress or patented dosing system may create separate legal risk.

Which excipient technology has the highest licensing value?

A validated taste-masking and suspension platform with comparative pediatric sensory data has the strongest licensing potential.

Does Children’s Allegra Allergy have biosimilar risk?

No. Fexofenadine is a small-molecule drug, not a biologic. The relevant competitive threats are generic, store-brand and private-label products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

2. U.S. Food and Drug Administration. (2024). DailyMed: Children’s Allegra Allergy fexofenadine hydrochloride oral suspension labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

4. U.S. Food and Drug Administration. (2024). Regulatory status of over-the-counter drug products marketed without an approved application. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.